Author:
Sonke Gabe S.,Hart Lowell L.,Campone Mario,Erdkamp Frans,Janni Wolfgang,Verma Sunil,Villanueva Cristian,Jakobsen Erik,Alba Emilio,Wist Erik,Favret Anne M.,Bachelot Thomas,Hegg Roberto,Wheatley-Price Paul,Souami Farida,Sutradhar Santosh,Miller Michelle,Germa Caroline,Burris Howard A.
Funder
The study was initiated, funded, and sponsored by Novartis Pharmaceuticals Corporation
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Howlader N, Noone A, Krapcho M et al (2016) SEER cancer statistics review, 1975–2013. National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/ . Accessed 24 Aug 2017
2. Howlader N, Altekruse S, Li C, Chen V, Clarke C, Ries L (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106:dju055
3. Riseberg D (2015) Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin Med Insights Oncol 9:65–73
4. Rugo H, Rumble R, Macrae E et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 34:3069–3103
5. Cardoso F, Costa A, Senkus E et al (2016) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28:16–33
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献